Pharmacokinetic studies of meloxicam after its intravenous administration in local goat (Capra hircus) of Assam

Wani, Abdul Rakeeb; Roy, Rohini Kumar; Ashraf, A. Q.; Roy, Dulal Chandra

doi:10.5455/vetworld.2013.516-520

Cited by 9 publications

(11 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,7 Meloxicam is a COX-2 selective NSAID that has been used extensively for its anti-inflammatory, analgesic, and antipyretic activity in some domestic animal species. [8][9][10][11] The pharmacokinetics of meloxicam has been evaluated in several species, including baboons, a mice, a horses, 12,13 donkeys, 13 sheep, 14,15 goats, 14,16,17 cattle, 18,19 dogs, 20,21,a vultures, 22 green iguanas, 23 cats, 24,25 piglets, 26,a camels, 27 llamas, 28 and rabbits. [29][30][31] Because no data are available for red-eared slider turtles (Trachemys scripta elegans), the dosage of meloxicam used in that species is routinely extrapolated from dosages for other species (ie, 0.1 to 0.2 mg/ kg, q 24 to 48 h).…”

Section: Aucmentioning

confidence: 99%

Pharmacokinetics of meloxicam in red-eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injections

Üney¹,

Altan²,

Aboubakr³

et al. 2016

ajvr

View full text Add to dashboard Cite

OBJECTIVE To determine the pharmacokinetics of meloxicam after single IV and IM injections in red-eared slider turtles (Trachemys scripta elegans). ANIMALS 8 healthy red-eared slider turtles. PROCEDURES Turtles received 1 dose of meloxicam (0.2 mg/kg) IV or IM (4 turtles/route), a 30-day washout period was provided, and then turtles received the same dose by the opposite route. Blood samples were collected at predetermined times for measurement of plasma meloxicam concentration. Pharmacokinetic values for each administration route were determined with a 2-compartment open model approach. RESULTS For IV administration, mean ± SD values of major pharmacokinetic variables were 1.02 ± 0.41 hours for distribution half-life, 9.78 ± 2.23 hours for elimination half-life, 215 ± 32 mL/kg for volume of distribution at steady state, 11.27 ± 1.44 μg•h/mL for area under the plasma concentration versus time curve, and 18.00 ± 2.32 mL/h/kg for total body clearance. For IM administration, mean values were 0.35 ± 0.06 hours for absorption half-life, 0.72 ± 0.06 μg/mL for peak plasma concentration, 1.5 ± 0.0 hours for time to peak concentration, 3.73 ± 2.41 hours for distribution half-life, 13.53 ± 1.95 hours for elimination half-life, 11.33 ± 0.92 μg•h/mL for area under the plasma concentration versus time curve, and 101 ± 6% for bioavailability. No adverse reactions were detected. CONCLUSIONS AND CLINICAL RELEVANCE Long half-life, high bioavailability, and lack of immediate adverse reactions of meloxicam administered IM at 0.2 mg/kg suggested the possibility of safe and effective clinical use in turtles. Additional studies are needed to establish appropriate administration frequency and clinical efficacy.

show abstract

Section: Aucmentioning

confidence: 99%

Pharmacokinetics of meloxicam in red-eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injections

Üney¹,

Altan²,

Aboubakr³

et al. 2016

ajvr

View full text Add to dashboard Cite

show abstract

“…In Canada, the use of meloxicam at an oral dose of 1 mg/kg in castration has been approved (Melendez et al., 2019). The dose of meloxicam recommended by European Medicines Agency (EMA) for use in goats is 0.5 mg/kg, whereas some studies have recommended the dose of 1 mg/kg (CVMP, 2006; Wani, Roy, Ashraf, & Roy, 2013). Meloxicam at doses of 1 and 2 mg/kg is quite effective in a sheep inflammation model (Colditz, Paull, Lloyd, Johnston, & Small, 2019; Woodland et al., 2019).…”

Section: Discussionmentioning

confidence: 99%

“…The minimum plasma concentration of meloxicam required for therapeutic effect in goats is 0.07 μg/ml (Wani et al, 2013). The effective plasma concentration (EC 50 ) of meloxicam for antipyretic and analgesic effects is 0.21 and 0.39 μg/ml, respectively, in the paw inflammation model in dogs and that for stride length and lameness are 0.13 and 0.2 μg/ml, respectively, in the arthritis model in horses (Jeunesse et al., 2011; Toutain & Cester, 2004).…”

Section: Discussionmentioning

confidence: 99%

Effect of castration procedure on the pharmacokinetics of meloxicam in goat kids

Tekeli

Türk

Çorum

et al. 2020

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

The aim of this study was to determine the changes in the pharmacokinetics of meloxicam in goat kids who were castrated following the administration of xylazine. Six goat kids were used for the study. The study was performed in two periods according to a longitudinal study, with a 15‐day washout period between periods. In the first period (Control group), 1 mg/kg meloxicam was administered by i.v. route to kids. In the second period (Castration group), the kids were sedated with 0.3 mg/kg xylazine and castration was performed following meloxicam administration. Plasma meloxicam concentration was analyzed using HPLC‐UV, and pharmacokinetic parameters were calculated by noncompartmental model. In the control group following the administration of meloxicam, mean elimination half‐life (t1/2ʎz), area under the concentration–time curve (AUC0−∞), total body clearance (ClT), and volume of distribution at steady‐state (Vdss) were 13.50 ± 0.62 hr, 41.10 ± 2.86 hr µg/ml, 24.43 ± 1.75 ml hr−1 kg−1, and 0.45 ± 0.03 L/kg, respectively. In the castration group, the t1/2ʎz of meloxicam prolonged, AUC0−∞ increased, and ClT and Vdss decreased. In conclusion, the excretion of meloxicam from the body slowed and the t1/2ʎz was prolonged in the castrated goat kids following xylazine administration. However, there is a need to determine the pharmacodynamics of meloxicam in castrated goat kids.

show abstract

“…There were few data reported in the literature regarding the intramuscular administration route of MEL in pigs, but studies have been carried out on the pharmacokinetics of MEL via intravenous administration extensively, and results showed that the t 1/2λz of MEL in plasma were 2.7 hr (0.4 mg/kg) in pigs (Fosse et al, ); 20.35 hr (0.5 mg/kg) and 21.86 hr (0.5 mg/kg) in calves (Coetzee, Kukanich, Kukanich, Mosher, & Allen, ; Coetzee et al, ); 5.29 hr (0.5 mg/kg) in horses (Pierre‐Louis & Cester, ); 8.08 hr (1 mg/kg), 6.73 hr (0.5 mg/kg), and 9.96 hr (0.5 mg/kg) in goats (De Vito et al, ; Shukla et al, ; Wani, Roy, Roy, Ashraf, & Roy, ); 11.54 hr (0.1 mg/kg) in beagle dogs (Junyi Hao & Cao, ); 3. 69 hr (1.5 mg/kg) in guinea pigs (Moeremans, Devreese, Devreese, Baere, Croubels, & Hermans, ); and 6.41 hr (10 mg/kg) in mice (Busch et al, ), revealing great interspecific variability.…”

Section: Discussionmentioning

confidence: 99%

“…(1 mg/kg), 6.73 hr (0.5 mg/kg), and 9.96 hr (0.5 mg/kg) in goats (De Vito et al, 2018;Shukla et al, 2007;Wani, Roy, Roy, Ashraf, & Roy, 2013); 11.54 hr (0.1 mg/kg) in beagle dogs (Junyi Hao & Cao, 2017);…”

Section: Uplc-ms/ms On Account Of the Low Mel Plasma Concentrationsmentioning

confidence: 99%

Pharmacokinetics and relative bioavailability of meloxicam oil suspension in pigs after intramuscular administration

Liu

Guo

Jiang

et al. 2019

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

This study aimed to develop one novel meloxicam (MEL) oil suspension for sustained‐release and compare the pharmacokinetic characteristics of it with MEL conventional formulation in pigs after a single intramuscular administration. Six healthy pigs were used for the study by a crossover design in two periods with a withdrawal interval of 14 days. Plasma concentrations of MEL were measured by ultra‐performance liquid chromatography–tandem mass spectrometry (UPLC‐MS/MS). Pharmacokinetic parameters were calculated by noncompartmental methods. The difference was statistically significant (p < .05) between MEL oil suspension and MEL conventional formulation in pharmacokinetic parameters of mean residence time (6.16 ± 4.04) hr versus (2.66 ± 0.55) hr, peak plasma concentration (Cmax) (0.82 ± 0.12) µg/ml versus (1.12 ± 0.22) µg/ml, time needed to reach Cmax (Tmax) (2.33 ± 0.82) hr versus (0.59 ± 0.18) hr, and terminal elimination half‐life (t1/2λz) (3.74 ± 2.66) hr versus (1.55 ± 0.37) hr. The mean area under the concentration–time curve (AUC0–∝) of MEL oil suspension and MEL conventional formulation was 5.35 and 3.43 hr µg/ml, respectively, with a relative bioavailability of 155.98%. Results of the present study demonstrated that the MEL oil suspension could prolong the effective time of drugs in blood, thereby reducing the frequency of administration on a course of treatment. Therefore, the novel MEL oil suspension seems to be of great value in veterinary clinical application.

show abstract

Pharmacokinetic studies of meloxicam after its intravenous administration in local goat (Capra hircus) of Assam

Cited by 9 publications

References 1 publication

Pharmacokinetics of meloxicam in red-eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injections

Pharmacokinetics of meloxicam in red-eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injections

Effect of castration procedure on the pharmacokinetics of meloxicam in goat kids

Pharmacokinetics and relative bioavailability of meloxicam oil suspension in pigs after intramuscular administration

Contact Info

Product

Resources

About